According to Xconomy, Alnylam has established these goals for itself to be reached in its RNAi business by 2015.
The goals include:
- Move 5 RNAi development programs into advanced clinicals by 2015
- Move new candidate for treatment of refractory anemia into clinic by 2012
- Establish new development parnerships
- End year with more than $275M in cash - which means spending less than $70 M (net)
As noted in a post yesterday, RNAi based therapy companies are finding it increasingly difficult to find new development partners - especially in the past couple down economic years. The technology has really not proven itself yet in the clinics - so Big Pharma appears to becoming more cautious in making new deals in this area. Thus, it may be very important indeed for Alnylam to strike a deal or two next year with new partners.
Posted by Bruce Lehr Jan 6th 2011.